RxDoctor Payments Data

Diane Cozzo

Adult Health · Buffalo, NYNPI 1215019930

Payments from drug & device makers

$4,206in general payments, 2019–2025

Across 257 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$952
  • Lilly USA, LLC$749
  • Pfizer$513
  • Amgen$474
  • AstraZeneca$320
  • Boehringer Ingelheim$216
  • plus $981 from 11 others

What the payments were for

  • Food & beverage$4,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,206 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$26,840
Medicare patients
126
Services billed
786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$169,068
JardianceEmpagliflozin131$136,598
OzempicSemaglutide57$68,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$64,106
XareltoRivaroxaban71$59,769
MounjaroTirzepatide49$57,414
XifaxanRifaximin17$55,623
RybelsusSemaglutide22$33,355
TrulicityDulaglutide24$31,720
Synjardy XrEmpagliflozin/Metformin Hcl27$28,164
SynjardyEmpagliflozin/Metformin Hcl26$15,353
LinzessLinaclotide13$11,684
EntrestoSacubitril/Valsartan11$11,407
Repatha SyringeEvolocumab11$10,296
SynthroidLevothyroxine Sodium129$10,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Stiolto Respimat$216$188,236201 claims
PfizerEliquis$513$169,068181 claims
Novo NordiskOzempic, Rybelsus$952$101,51879 claims
Lilly USA, LLCMounjaro, Trulicity$749$89,13473 claims
GSKTrelegy Ellipta$128$64,10685 claims
AbbVieLinzess, Synthroid, Creon$120$27,859155 claims
NovartisEntresto$50$11,40711 claims
AstraZenecaBrilinta, Symbicort$320$9,00832 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$149$5,80613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.

Other adult health in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →